1
|
Acoustic startle and prepulse inhibition deficits in adult monkeys with neonatal lesions of the hippocampus, amygdala and orbital frontal cortex. Behav Brain Res 2023; 438:114170. [PMID: 36283567 DOI: 10.1016/j.bbr.2022.114170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 10/17/2022] [Accepted: 10/19/2022] [Indexed: 12/05/2022]
Abstract
Sensory-motor gating, the process of filtering sensory stimuli to modulate motor responses, is impaired in many psychiatric diseases but especially schizophrenia. Sensory-motor gating assessed with the prepulse inhibition paradigm (PPI) measures startle in response to preceding acoustic stimuli. PPI studies in rodents have consistently found that neonatal hippocampal lesions impair sensory-motor gating in adult animals, but its applicability to primates has yet to be tested. The study examined acoustic startle responses and PPI in adult rhesus monkeys with neonatal lesions of the hippocampus (Neo-Hibo), amygdala (Neo-Aibo), and orbital frontal cortex areas 11 and 13 (Neo-Oasp) and with sham-operations (Neo-C). All monkeys were initially habituated to the startle apparatus and assayed for acoustic startle response curves. Subsequently, PPI was measured with the prepulse occurring at 60, 120, 240, 480, 1000 and 5000 msec prior to the pulse onset. No significant group differences in baseline startle were found. Compared to Neo-C monkeys, Neo-Hibo monkeys showed normal startle curves as well as normal PPI at short prepulse delays but prepulse facilitation (PPF) at longer prepulse intervals. Neo-Aibo monkeys displayed enhanced startle responses with only minor changes in PPI, whereas Neo-Oasp monkeys had severe dampening of startle responses and impaired PPI at shorter prepulse intervals. These results support prior evidence from rodent literature of the involvement of each of these areas in the development of the complex cortico-limbic circuit modulating sensory-motor gating and may shade light on the specific neural structures associated with deficits in PPI reported in neuropsychiatric disorders, such as schizophrenia, autism spectrum disorders, and post-traumatic disorders.
Collapse
|
2
|
Ten-Blanco M, Pereda-Pérez I, Izquierdo-Luengo C, Berrendero F. CB2 cannabinoid receptor expression is increased in 129S1/SvImJ mice: behavioral consequences. Front Pharmacol 2022; 13:975020. [PMID: 36081934 PMCID: PMC9445237 DOI: 10.3389/fphar.2022.975020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2022] [Accepted: 07/25/2022] [Indexed: 11/13/2022] Open
Abstract
Genetic and environmental factors are implicated in the etiology of neuropsychiatric diseases. Inbred mouse strains, including the 129S1/SvImJ (S1), constitute important models to study the influence of genetic factors in these conditions. S1 mice displayed anxiogenic-like behavior, impaired fear extinction, and increased prepulse inhibition (PPI) of startle reflex compared to C57BL/6J (BL6) mice. Given the role played by the endocannabinoid system (ECS) in these responses, we evaluated the expression of the ECS components in different brain regions in S1 mice. Gene expression levels of the cannabinoid type-1 and type-2 receptors (CB1R and CB2R) and the endocannabinoid metabolizing enzymes varied depending on the brain region evaluated. Notably, CB2R expression markedly increased in the amygdala, prefrontal cortex and hippocampus in S1 mice. Moreover, CB2R blockade with SR144528 partially rescued the anxiogenic phenotype in S1 mice, while CB2R activation with JWH133 potentiated the deficits in fear extinction and the PPI of startle reflex in this mouse strain. These data suggest that CB2R is involved in the behavioral alterations observed in S1 mice and underline the importance of this cannabinoid receptor subtype in the regulation of certain central nervous system disorders.
Collapse
|
3
|
Involvement of the thalamic reticular nucleus in prepulse inhibition of acoustic startle. Transl Psychiatry 2021; 11:241. [PMID: 33895779 PMCID: PMC8068728 DOI: 10.1038/s41398-021-01363-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/27/2020] [Revised: 03/23/2021] [Accepted: 04/08/2021] [Indexed: 12/12/2022] Open
Abstract
Thalamic reticular nucleus (TRN) is a group of inhibitory neurons surrounding the thalamus. Due to its important role in sensory information processing, TRN is considered as the target nucleus for the pathophysiological investigation of schizophrenia and autism spectrum disorder (ASD). Prepulse inhibition (PPI) of acoustic startle response, a phenomenon that strong stimulus-induced startle reflex is reduced by a weaker prestimulus, is always found impaired in schizophrenia and ASD. But the role of TRN in PPI modulation remains unknown. Here, we report that parvalbumin-expressing (PV+) neurons in TRN are activated by sound stimulation of PPI paradigm. Chemogenetic inhibition of PV+ neurons in TRN impairs PPI performance. Further investigations on the mechanism suggest a model of burst-rebound burst firing in TRN-auditory thalamus (medial geniculate nucleus, MG) circuitry. The burst firing is mediated by T-type calcium channel in TRN, and rebound burst firing needs the participation of GABAB receptor in MG. Overall, these findings support the involvement of TRN in PPI modulation.
Collapse
|
4
|
Wang J, Yu W, Gao Q, Ju C, Wang K. Prefrontal inhibition of neuronal K v 7 channels enhances prepulse inhibition of acoustic startle reflex and resistance to hypofrontality. Br J Pharmacol 2020; 177:4720-4733. [PMID: 32839968 PMCID: PMC7520443 DOI: 10.1111/bph.15236] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2020] [Revised: 07/31/2020] [Accepted: 08/06/2020] [Indexed: 11/28/2022] Open
Abstract
Background and Purpose Dysfunction of the prefrontal cortex (PFC) is involved in the cognitive deficits in neuropsychiatric diseases, such as schizophrenia, characterized by deficient neurotransmission known as NMDA receptor hypofrontality. Thus, enhancing prefrontal activity may alleviate hypofrontality‐induced cognitive deficits. To test this hypothesis, we investigated the effect of forebrain‐specific suppression or pharmacological inhibition of native Kv7/KCNQ/M‐current on glutamatergic hypofrontality induced by the NMDA receptor antagonist MK‐801. Experimental Approach The forebrain‐specific inhibition of native M‐current was generated by transgenic expression, in mice, of a dominant‐negative pore mutant G279S of Kv7.2/KCNQ2 channels that suppresses channel function. A mouse model of cognitive impairment was established by single i.p. injection of 0.1 mg·kg−1 MK‐801. Mouse models of prepulse inhibition (PPI) of acoustic startle reflex and Y‐maze spontaneous alternation test were used for evaluation of cognitive behaviour. Hippocampal brain slice recordings of LTP were used to assess synaptic plasticity. Hippocampus and cortex were dissected for detecting protein expression using western blot analysis. Key Results Genetic suppression of Kv7 channel function in the forebrain or pharmacological inhibition of Kv7 channels by the specific blocker XE991 enhanced PPI and also alleviated MK‐801 induced cognitive decline. XE991 also attenuated MK‐801‐induced LTP deficits and increased basal synaptic transmissions. Western blot analysis revealed that inhibiting Kv7 channels resulted in elevation of pAkt1 and pGSK‐3β expressions in both hippocampus and cortex. Conclusions and Implications Both genetic and pharmacological inhibition of Kv7 channels alleviated PPI and cognitive deficits. Mechanistically, inhibition of Kv7 channels promotes synaptic transmission and activates Akt1/GSK‐3β signalling.
Collapse
Affiliation(s)
- Jing Wang
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China
| | - Wenwen Yu
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.,Institute of Innovative Drugs, Qingdao University, Qingdao, China
| | - Qin Gao
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China
| | - Chuanxia Ju
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China
| | - KeWei Wang
- Department of Pharmacology, School of Pharmacy, Qingdao University, Qingdao, China.,Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangzhou, China.,Institute of Innovative Drugs, Qingdao University, Qingdao, China
| |
Collapse
|
5
|
Baba M, Yokoyama K, Seiriki K, Naka Y, Matsumura K, Kondo M, Yamamoto K, Hayashida M, Kasai A, Ago Y, Nagayasu K, Hayata-Takano A, Takahashi A, Yamaguchi S, Mori D, Ozaki N, Yamamoto T, Takuma K, Hashimoto R, Hashimoto H, Nakazawa T. Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome. Neuropsychopharmacology 2019; 44:2125-2135. [PMID: 31216562 PMCID: PMC6887869 DOI: 10.1038/s41386-019-0441-5] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/18/2019] [Revised: 06/03/2019] [Accepted: 06/10/2019] [Indexed: 01/23/2023]
Abstract
3q29 microdeletion, a rare recurrent copy number variant (CNV), greatly confers an increased risk of psychiatric disorders, such as schizophrenia and autism spectrum disorder (ASD), as well as intellectual disability. However, disease-relevant cellular phenotypes of 3q29 deletion syndrome remain to be identified. To reveal the molecular and cellular etiology of 3q29 deletion syndrome, we generated a mouse model of human 3q29 deletion syndrome by chromosome engineering, which achieved construct validity. 3q29 deletion (Df/+) mice showed reduced body weight and brain volume and, more importantly, impaired social interaction and prepulse inhibition. Importantly, the schizophrenia-related impaired prepulse inhibition was reversed by administration of antipsychotics. These findings are reminiscent of the growth defects and neuropsychiatric behavioral phenotypes in patients with 3q29 deletion syndrome and exemplify that the mouse model achieves some part of face validity and predictive validity. Unbiased whole-brain imaging revealed that neuronal hyperactivation after a behavioral task was strikingly exaggerated in a restricted region of the cortex of Df/+ mice. We further elucidated the cellular phenotypes of neuronal hyperactivation and the reduction of parvalbumin expression in the cortex of Df/+ mice. Thus, the 3q29 mouse model provides invaluable insight into the disease-causative molecular and cellular pathology of psychiatric disorders.
Collapse
Affiliation(s)
- Masayuki Baba
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Kazumasa Yokoyama
- 0000 0001 0673 6017grid.419841.1Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa Fujisawa, 251-8555 Japan
| | - Kaoru Seiriki
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0373 3971grid.136593.bInterdisciplinary Program for Biomedical Sciences, Institute for Transdisciplinary Graduate Degree Programs, Osaka University, Suita, Osaka 565-0871 Japan
| | - Yuichiro Naka
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Kensuke Matsumura
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0373 3971grid.136593.bInterdisciplinary Program for Biomedical Sciences, Institute for Transdisciplinary Graduate Degree Programs, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0614 710Xgrid.54432.34Research Fellowships for Young Scientists of the Japan Society for the Promotion of Science, Chiyoda-ku, Tokyo, 102-0083 Japan
| | - Momoka Kondo
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Kana Yamamoto
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Misuzu Hayashida
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Atsushi Kasai
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Yukio Ago
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0373 3971grid.136593.bLaboratory of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Kazuki Nagayasu
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan
| | - Atsuko Hayata-Takano
- 0000 0004 0373 3971grid.136593.bLaboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0373 3971grid.136593.bMolecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka 565-0871 Japan
| | - Akinori Takahashi
- 0000 0000 9805 2626grid.250464.1Cell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, 904-0495 Japan
| | - Shun Yamaguchi
- 0000 0004 0370 4927grid.256342.4Department of Morphological Neuroscience, Gifu University Graduate School of Medicine, Gifu, 501-1194 Japan ,0000 0004 0370 4927grid.256342.4Center for Highly Advanced Integration of Nano and Life Sciences, Gifu University, Gifu, 501-1194 Japan
| | - Daisuke Mori
- 0000 0001 0943 978Xgrid.27476.30Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Nagoya, 466-8550 Japan ,0000 0001 0943 978Xgrid.27476.30Brain and Mind Research Center, Nagoya University, Aichi, Nagoya, 466-8550 Japan
| | - Norio Ozaki
- 0000 0001 0943 978Xgrid.27476.30Department of Psychiatry, Nagoya University Graduate School of Medicine, Aichi, Nagoya, 466-8550 Japan
| | - Tadashi Yamamoto
- 0000 0000 9805 2626grid.250464.1Cell Signal Unit, Okinawa Institute of Science and Technology Graduate University, Onna-son, Okinawa, 904-0495 Japan ,0000000094465255grid.7597.cLaboratory for Immunogenetics, Center for Integrative Medical Sciences, RIKEN, Kanagawa Yokohama, 230-0045 Japan
| | - Kazuhiro Takuma
- 0000 0004 0373 3971grid.136593.bMolecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka 565-0871 Japan ,0000 0004 0373 3971grid.136593.bDepartment of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka 565-0871 Japan
| | - Ryota Hashimoto
- 0000 0004 1763 8916grid.419280.6Department of Pathology of Mental Diseases, National Institute of Mental Health, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8553 Japan ,0000 0004 0373 3971grid.136593.bOsaka University, Suita, Osaka 565-0871 Japan
| | - Hitoshi Hashimoto
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. .,Molecular Research Center for Children's Mental Development, United Graduate School of Child Development, Osaka University, Suita, Osaka, 565-0871, Japan. .,Division of Bioscience, Institute for Datability Science, Osaka University, Suita, Osaka, 565-0871, Japan. .,Transdimensional Life Imaging Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Osaka, 565-0871, Japan.
| | - Takanobu Nakazawa
- Laboratory of Molecular Neuropharmacology, Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, 565-0871, Japan. .,Department of Pharmacology, Graduate School of Dentistry, Osaka University, Suita, Osaka, 565-0871, Japan.
| |
Collapse
|
6
|
Schneider ML, Moore CF, Ahlers EO, Barnhart TE, Christian BT, DeJesus OT, Engle JW, Holden JE, Larson JA, Moirano JM, Murali D, Nickles RJ, Resch LM, Converse AK. PET Measures of D1, D2, and DAT Binding Are Associated With Heightened Tactile Responsivity in Rhesus Macaques: Implications for Sensory Processing Disorder. Front Integr Neurosci 2019; 13:29. [PMID: 31379528 PMCID: PMC6652150 DOI: 10.3389/fnint.2019.00029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2019] [Accepted: 07/02/2019] [Indexed: 01/11/2023] Open
Abstract
Sensory processing disorder (SPD), a developmental regulatory condition characterized by marked under- or over-responsivity to non-noxious sensory stimulation, is a common but poorly understood disorder that can profoundly affect mood, cognition, social behavior and adaptive life skills. Little is known about the etiology and neural underpinnings. Clinical research indicates that children with SPD show greater prevalence of difficulties in complex cognitive behavior including working memory, behavioral flexibility, and regulation of sensory and affective functions, which are related to prefrontal cortex (PFC), striatal, and midbrain regions. Neuroimaging may provide insight into mechanisms underlying SPD, and animal experiments provide important evidence that is not available in human studies. Rhesus monkeys (N = 73) were followed over a 20-year period from birth into old age. We focused on a single sensory modality, the tactile system, measured at 5-7 years, because of its critical importance for nourishment, attachment, and social reward in development. Positron emission tomography imaging was conducted at ages 12-18 years to quantify the availability of the D1 and D2 subtypes of the DA receptor (D1R and D2R), and the DA transporter (DAT). Heightened tactile responsivity was related to (a) elevated D1R in PFC overall, including lateral, ventrolateral, medial, anterior cingulate (aCg), frontopolar, and orbitofrontal (OFC) subregions, as well as nucleus accumbens (Acb), (b) reduced D2R in aCg, OFC, and substantia nigra/ventral tegmental area, and (c) elevated DAT in putamen. These findings suggest a mechanism by which DA pathways may be altered in SPD. These pathways are associated with reward processing and pain regulation, providing top-down regulation of sensory and affective processes. The balance between top-down cognitive control in the PFC-Acb pathway and bottom-up motivational function of the VTA-Acb-PFC pathway is critical for successful adaptive function. An imbalance in these two systems might explain DA-related symptoms in children with SPD, including reduced top-down regulatory function and exaggerated responsivity to stimuli. These results provide more direct evidence that SPD may involve altered DA receptor and transporter function in PFC, striatal, and midbrain regions. More work is needed to extend these results to humans.
Collapse
Affiliation(s)
- Mary L Schneider
- Occupational Therapy Program, Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, United States.,Harlow Center for Biological Psychology, University of Wisconsin-Madison, Madison, WI, United States
| | - Colleen F Moore
- Department of Psychology, University of Wisconsin-Madison, Madison, WI, United States.,Department of Psychology, Montana State University, Bozeman, MT, United States
| | - Elizabeth O Ahlers
- Waisman Center, University of Wisconsin-Madison, Madison, WI, United States
| | - Todd E Barnhart
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Bradley T Christian
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Onofre T DeJesus
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Jonathan W Engle
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - James E Holden
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Julie A Larson
- Occupational Therapy Program, Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, United States.,Harlow Center for Biological Psychology, University of Wisconsin-Madison, Madison, WI, United States
| | - Jeffrey M Moirano
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Dhanabalan Murali
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Robert J Nickles
- Department of Medical Physics, University of Wisconsin-Madison, Madison, WI, United States
| | - Leslie M Resch
- Occupational Therapy Program, Department of Kinesiology, University of Wisconsin-Madison, Madison, WI, United States.,Harlow Center for Biological Psychology, University of Wisconsin-Madison, Madison, WI, United States
| | | |
Collapse
|
7
|
Erdozain AM, Brocos-Mosquera I, Gabilondo AM, Meana JJ, Callado LF. Differential α 2A- and α 2C-adrenoceptor protein expression in presynaptic and postsynaptic density fractions of postmortem human prefrontal cortex. J Psychopharmacol 2019; 33:244-249. [PMID: 30255728 DOI: 10.1177/0269881118798612] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Three different α2-adrenoceptor (α2-AR) subtypes have been described. The α2A-AR and α2C-AR subtypes are highly expressed in the human prefrontal cortex, where they modulate neurotransmission. However, due to the lack of subtype-selective ligands, the physiological relevance of both subtypes has not been fully resolved. AIMS In this context, the aim of the present study was to characterize the protein expression of both α2-AR subtypes, in different synaptic fractions of postmortem human prefrontal cortex. METHODS A subcellular fractionation of the samples was performed and the protein expression of α2A- and α2C-ARs was measured in presynaptic membranes and postsynaptic density fractions by Western blot. RESULTS The results revealed that the α2A-AR subtype is mainly located postsynaptically (95±3%) whereas the remaining 5±3% is in the presynapse. Conversely, the α2C-AR subtype showed a similar distribution between pre- and postsynaptic membranes, with a slightly higher percentage present in the presynapse (60±2% vs. 40±2%). CONCLUSIONS These findings could explain some contradictory effects reported for α2-AR agonists and antagonists in the human prefrontal cortex. Furthermore, the present data could contribute to elucidating the therapeutic potential of selectively targeting α2A- or α2C-AR subtypes.
Collapse
Affiliation(s)
- Amaia M Erdozain
- 1 Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.,2 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain
| | - Iria Brocos-Mosquera
- 1 Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain
| | - Ane M Gabilondo
- 1 Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.,2 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.,3 Biocruces Health Research Institute, Barakaldo, Spain
| | - J Javier Meana
- 1 Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.,2 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.,3 Biocruces Health Research Institute, Barakaldo, Spain
| | - Luis F Callado
- 1 Department of Pharmacology, University of the Basque Country, UPV/EHU, Leioa, Spain.,2 Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.,3 Biocruces Health Research Institute, Barakaldo, Spain
| |
Collapse
|